Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium.


Journal

Current microbiology
ISSN: 1432-0991
Titre abrégé: Curr Microbiol
Pays: United States
ID NLM: 7808448

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 31 07 2018
accepted: 19 12 2018
pubmed: 4 1 2019
medline: 13 7 2019
entrez: 4 1 2019
Statut: ppublish

Résumé

Cell wall hydrolases are enzymes that cleave bacterial cell walls by hydrolyzing specific bonds within peptidoglycan and other portions of the envelope. Two major sources of hydrolases in nature are from hosts and microbes. This study specifically investigated whether cell wall hydrolytic enzymes could be employed as exogenous reagents to augment the efficacy of antimicrobial agents against mycobacteria. Mycobacterium smegmatis cultures were treated with ten conventional antibiotics and six anti-tuberculosis drugs-alone or in combination with cell wall hydrolases. Culture turbidity, colony-forming units (CFUs), vital staining, and oxygen consumption were all monitored. The majority of antimicrobial agents tested alone only had minimal inhibitory effects on bacterial growth. However, the combination of cell wall hydrolases and most of the antimicrobial agents tested, revealed a synergistic effect that resulted in significant enhancement of bactericidal activity. Vital staining showed increased cellular damage when M. smegmatis and Mycobacterium bovis bacillus Calmette-Guérin (M. bovis BCG) were treated with both drug and lysozyme. Respiration analysis revealed stress responses when cells were treated with lysozyme and drugs individually, and an acute increase in oxygen consumption when treated with both drug and lysozyme. Similar trends were also observed for the other three enzymes (hydrolase-30, RipA-His

Identifiants

pubmed: 30603964
doi: 10.1007/s00284-018-1620-z
pii: 10.1007/s00284-018-1620-z
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antitubercular Agents 0
Hydrolases EC 3.-
Oxygen S88TT14065

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

398-409

Références

Mol Microbiol. 2003 Apr;48(1):77-84
pubmed: 12657046
J Antimicrob Chemother. 2003 Jul;52(1):61-4
pubmed: 12805268
Clin Microbiol Rev. 2003 Jul;16(3):463-96
pubmed: 12857778
Mol Microbiol. 2003 Sep;49(5):1167-77
pubmed: 12940978
Biochim Biophys Acta. 2005 Feb 14;1747(1):57-66
pubmed: 15680239
Antimicrob Agents Chemother. 2005 Mar;49(3):1225-8
pubmed: 15728935
Mol Microbiol. 2006 Dec;62(6):1569-85
pubmed: 17083467
PLoS Med. 2007 Mar;4(3):e120
pubmed: 17388672
PLoS Med. 2007 Jul 24;4(7):e238
pubmed: 17676945
Mol Microbiol. 2007 Nov;66(3):658-68
pubmed: 17919286
Microbiol Mol Biol Rev. 2008 Mar;72(1):126-56, table of contents
pubmed: 18322037
J Infect Dis. 1991 Mar;163(3):574-8
pubmed: 1899873
Antimicrob Agents Chemother. 2010 Apr;54(4):1603-12
pubmed: 20086153
J Biosci. 2010 Mar;35(1):127-60
pubmed: 20413917
Mol Microbiol. 2010 Aug;77(3):672-86
pubmed: 20545844
MBio. 2011 Jun 14;2(3):e00100-11
pubmed: 21673191
J Biol Chem. 1990 Oct 25;265(30):18200-6
pubmed: 2211696
Appl Environ Microbiol. 2013 Feb;79(3):768-73
pubmed: 23160121
Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2100-9
pubmed: 24803433
Enzyme Microb Technol. 2014 Sep;63:1-6
pubmed: 25039052
Crit Rev Biotechnol. 2016 Dec;36(6):1078-1088
pubmed: 26383819
Clin Infect Dis. 2016 Oct 1;63(7):e147-e195
pubmed: 27516382
Lancet Respir Med. 2018 Apr;6(4):299-314
pubmed: 29595511
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29987141
J Infect Dis. 1988 Jul;158(1):52-9
pubmed: 3392420
Annu Rev Biochem. 1995;64:29-63
pubmed: 7574484
Antimicrob Agents Chemother. 1995 Mar;39(3):694-701
pubmed: 7793875
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8916-21
pubmed: 9671779
Front Biosci. 1998 Dec 15;3:D1253-61
pubmed: 9851911

Auteurs

Joshua N Gustine (JN)

Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

Matthew B Au (MB)

Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

John R Haserick (JR)

Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

Erik C Hett (EC)

Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.
Merck, Exploratory Science Center, Chemical Biology, Cambridge, MA, USA.

Eric J Rubin (EJ)

Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.

Frank C Gibson (FC)

Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA.

Lingyi L Deng (LL)

Department of Medicine, Boston University School of Medicine, Boston, MA, USA. lynndeng@bu.edu.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Humans China Cerebral Hemorrhage Patient Care Bundles Length of Stay

Classifications MeSH